Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Transplant Cell Ther. 2021 Apr 6;27(8):632–641. doi: 10.1016/j.jtct.2021.03.029

Table 6.

Features of Ideal Preemptive Therapeutic Agents

Feature Considerations
Biological rationale - Selection of interventions that target pathways implicated in chronic GVHD pathogenesis
Safety - Low toxicity, limited interactions with medications given after HCT
- Risk profile of intervention commensurate with severity of outcome to be prevented (and PPV of the assessment/biomarker)
- When possible, minimize disruption of graft-versus-malignancy effects
Tolerability/cost - Ensure intervention adherence
- Allow prolonged therapy to prevent late occurring chronic GVHD events
- Patient and health care system able to afford treatment
Efficacy - Prioritization of agents with demonstrated activity in chronic GVHD therapy or allied human immune-mediated disorders
Transportability - Logistics of delivering therapy permit dissemination
- Orally available agents generally preferred
HHS Vulnerability Disclosure